- Filings
-
Holdings
-
Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
Profile
- Financials
Avenue Therapeutics (ATXI)
Company Profile
| Quarter (USD) | Jun 25 | Mar 25 | Dec 24 | Sep 24 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 3.33 mm | 3.33 mm | 3.33 mm | 3.33 mm | 3.33 mm | 3.33 mm |
| Cash burn (monthly) | 58.67 k | 132.75 k | (no burn) | 530.00 k | 58.67 k | 417.92 k |
| Cash used (since last report) | 258.02 k | 583.85 k | n/a | 2.33 mm | 258.02 k | 1.84 mm |
| Cash remaining | 3.07 mm | 2.74 mm | n/a | 995.00 k | 3.07 mm | 1.49 mm |
| Runway (months of cash) | 52.3 | 20.7 | n/a | 1.9 | 52.3 | 3.6 |
| 13F holders | Current |
|---|---|
| Total holders | 12 |
| Opened positions | 7 |
| Closed positions | 2 |
| Increased positions | 0 |
| Reduced positions | 2 |
| 13F shares | Current |
|---|---|
| Total value | 386.39 mm |
| Total shares | 1.06 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| FBIO Fortress Biotech | 295.02 k | $389.00 k |
| CVI Investments | 251.01 k | $0.00 |
| Intracoastal Capital | 216.79 k | $616.00 k |
| Ikarian Capital | 140.00 k | $280.00 mm |
| Armistice Capital | 100.40 k | $133.00 k |
| Boothbay Fund Management | 41.09 k | $82.18 mm |
| UBS UBS | 7.92 k | $15.84 mm |
| Tower Research Capital | 3.10 k | $6.19 mm |
| WFC Wells Fargo & Company | 500.00 | $1.00 mm |
| BAC Bank of America | 14.00 | $28.00 k |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 31 Mar 25 | Fortress Biotech | COMMON STOCK, PAR VALUE $0.0001 | Grant | Acquire A | No | No | 0 | 33,724 | 0.00 | 328,524 |
| 2 Dec 24 | Neil Herskowitz | COMMON STOCK, PAR VALUE $0.0001 | Sell | Dispose S | No | No | 2 | 23 | 46.00 | 97 |
| 5 Nov 24 | Kranzler Jay D | COMMON STOCK, PAR VALUE $0.0001 | Sell | Dispose S | No | No | 2.24 | 61 | 136.64 | 559 |
| 30 Sep 24 | Kranzler Jay D | COMMON STOCK, PAR VALUE $0.0001 | Buy | Acquire P | No | No | 2.5 | 497 | 1.24 k | 620 |
| 27 Sep 24 | Kranzler Jay D | COMMON STOCK, PAR VALUE $0.0001 | Buy | Acquire P | No | No | 2.4 | 3 | 7.20 | 123 |